Global High-Priority Regulatory Events — March 12, 2026

12-03-2026

Acurx Pharmaceuticals, Inc. (ACXP) filed its 10-K Annual Report on March 12, 2026, detailing significant risk factors including ongoing net losses since inception with no anticipated profitability in the foreseeable future. Key risks encompass potential failure to obtain regulatory approval for product candidate ibezapolstat, challenges in establishing sales/marketing capabilities, reimbursement limitations from third-party payers, high commercialization costs, supply chain disruptions, and international uncertainties such as Brexit. While the company believes ibezapolstat can be priced competitively due to low manufacturing costs compared to generics like vancomycin and metronidazole for CDI treatment, commercialization remains uncertain.

12-03-2026

Horizon Kinetics Holding Corp's 2025 revenue rose 31% YoY to $72.8M from $55.8M, driven by 31% growth in management and advisory fees to $72.4M, while operating expenses fell 13% to $61.8M, swinging operating income to a $11.1M profit from a $15.1M loss. However, net income attributable to HKHC plummeted 95% to $5.1M from $92.5M, primarily due to a sharp drop in net investment income of consolidated products to -$17.8M from $840.7M and unrealized investment losses; operating cash flow turned negative at -$43.1M from $11.8M positive. Total assets edged down 1.6% to $2.0B, though cash equivalents more than doubled to $36.9M.

• ·EPS attributable to HKHC: $0.27 (2025) vs $5.07 (2024)
• ·Dividends paid: $6.3M (2025) vs $1.0M (2024)
• ·Deferred tax liability declined to $66.3M from $95.7M

12-03-2026

Churchill Downs Incorporated (CHDN) filed its DEF 14A proxy statement dated March 12, 2026, for the virtual Annual Meeting on April 21, 2026, at 9:00 a.m. ET, soliciting votes to elect two Class III directors (plurality vote), ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 (majority vote), and approve executive compensation on an advisory basis (majority vote). As of the record date March 2, 2026, 69,696,376 shares of common stock were outstanding, with the Board unanimously recommending 'FOR' all proposals; no financial performance metrics or period comparisons are detailed.

• ·Annual Meeting registration deadline: April 19, 2026 at 5:00 p.m. ET at www.proxydocs.com/CHDN.
• ·Quorum requires majority of outstanding shares present virtually or by proxy.
• ·Abstentions treated as 'against' for Proposals 2 and 3; broker non-votes have no effect on Proposals 1 and 3.

12-03-2026

Grayscale Zcash Trust (ZCSH), which holds approximately 2.4% of ZEC in circulation as of December 31, 2025, reported shares outstanding of 4,829,300 as of March 6, 2026, with non-affiliate market value of $14.4M as of June 30, 2025. While the Trust plans to convert to an ETF structure with NYSE Arca listing and redemption program pending SEC approval, shares have historically traded at substantial premiums (max 240%, avg 53%) and discounts (max 55%, avg 20%, with 583 discount days), ending the year at a 24% discount to NAV per Share. Each Share represented 0.0815 ZEC as of year-end.

• ·Trust formed on October 23, 2017; name changed January 11, 2019.
• ·Sponsor changes: Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole Sponsor effective May 3, 2025.
• ·S-3 registration filed November 2025 for potential public offering and NYSE Arca listing under ZCSH.

12-03-2026

Enanta Pharmaceuticals held its Annual Meeting on March 11, 2026, where stockholders re-elected directors Bruce L.A. Carter, Ph.D. and Jay R. Luly, Ph.D.; approved an amendment to the 2019 Equity Incentive Plan to increase reserved shares by 1,600,000 despite 5,390,888 votes against; approved the say-on-pay proposal; and ratified PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending September 30, 2026. All proposals passed with strong support overall, though the equity plan amendment faced notable opposition representing about 22% of votes cast.

• ·Proposal 1 (Director Elections): Carter - 20,289,217 For, 4,634,123 Withheld; Luly - 24,728,854 For, 194,486 Withheld; 1,929,393 Broker Non-Votes.
• ·Proposal 2: 19,528,223 For, 5,390,888 Against, 4,229 Abstain.
• ·Proposal 3 (Say-on-Pay): 24,228,898 For, 692,079 Against, 2,363 Abstain.
• ·Proposal 4 (Auditors): 26,825,173 For, 26,904 Against, 656 Abstain, 0 Broker Non-Votes.
• ·Definitive proxy statement filed January 26, 2026.

12-03-2026

Healthpeak Properties, Inc. (NYSE: DOC), an S&P 500 REIT with a $25B healthcare real estate portfolio including 689 properties, 50M sq ft in Outpatient Medical and Lab, and 10,422 Senior Housing units as of December 31, 2025, filed its 2026 definitive proxy statement ahead of its annual stockholder meeting. 2025 performance highlights include Nareit FFO of $1.81 per share, Diluted FFO as Adjusted of $1.84 per share, 4% Merger-Combined Same-Store Cash (Adjusted) NOI growth YoY, 6.3M sq ft in total leasing volume, and a 7% annualized dividend yield based on $1.22 per share, supported by investment-grade ratings of S&P BBB+ (Stable) and Moody’s Baa1 (Stable) with net debt to Adjusted EBITDAre at 5.2x. The proxy seeks stockholder approval for director elections, an advisory vote on 2025 executive compensation (featuring PEO Scott M. Brinker), and ratification of the independent auditor.

• ·Headquartered in Denver, CO with offices in CA, TN, WI, MA; S&P 500 and NYSE-listed (DOC); 40 years as public company
• ·Maintains investment-grade credit ratings: S&P BBB+ (Stable), Moody’s Baa1 (Stable)

12-03-2026

Primeage Technology Group Co., Ltd., a blank check company (SPAC) incorporated in the British Virgin Islands, filed a preliminary F-1 registration statement for an IPO of 10,000,000 ordinary shares at $10.00 each, aiming to raise $100M to pursue an initial business combination, primarily targeting businesses in China and the Asia-Pacific region. Proceeds net of $2M underwriting discounts will total $98M before expenses and be held in a U.S. trust account, with public shareholders able to redeem shares at the completion of a deal or if no combination occurs within 24 months from closing. The company is an emerging growth company and smaller reporting company, with no target selected and high investment risks highlighted.

• ·Intends to list ordinary shares on Nasdaq Global Market under symbol 'PRAG'
• ·No business combination target selected or substantive discussions initiated
• ·Redemption of public shares if no business combination within 24 months from IPO closing
• ·Deposited proceeds held in U.S.-based trust account until business combination, shareholder vote, or liquidation
• ·Filing date: March 11, 2026; principal offices in Beijing, China

12-03-2026

Sonida Senior Living, Inc. reported resident revenue growth of 23.9% YoY to $332M for FY 2025, driven by expansion to 80 communities (+3.9%) and higher RevPAR (+7.9%), with community NOI up 21.6% to $83M and Adjusted EBITDA rising 24.3% to $54M. However, net loss widened dramatically to $72.5M from $3.3M due to $12.5M long-lived asset impairment, higher depreciation (+28.9%), transaction costs ($16.2M), and no repeat of prior year's $48.5M debt extinguishment gain, while overall occupancy dipped 0.7% to 84.7%. Same-store revenue grew modestly 6.1% with NOI up 8.0%, but average units were flat at +0.2%.

• ·Management fee revenue increased 31.1% YoY to $4.4M.
• ·Transaction, transition and restructuring costs rose to $16.2M from $5.9M.
• ·Interest expense up 4.4% to $38.6M.
• ·Net cash used in investing activities improved to $70.7M outflow from $209M.
• ·Investment Agreements dated November 4, 2025 with Conversant entities and Silk Partners, LP.
• ·Amended and Restated Investor Rights Agreement dated March 10, 2026.

12-03-2026

Orrstown Financial Services reported average total assets of $5.43B in 2025, up 25.7% YoY from $4.32B, fueled by 25.2% loan growth to $3.95B average balance and net interest income expansion of 28.7% to $199.8M with NIM improving to 4.04%. Noninterest income surged 39.7% YoY to $52.3M, driven by trust/brokerage and swap fees, while noninterest expenses remained nearly flat at $149.4M (up 0.7%) due to sharply lower merger-related costs ($2.6M vs $22.7M). However, mortgage banking income declined 1.6% YoY and investment securities gains fell 33.3%.

• ·Accretion on purchase accounting marks: $21.5M in 2025 (vs $15.2M in 2024)
• ·Merger-related expenses: $2.6M in 2025 (down from $22.7M in 2024)
• ·Investment securities portfolio book value $972.1M with average maturity 23.3 years
• ·Salaries and employee benefits up 11.2% YoY to $85.2M

12-03-2026

Grayscale XRP Trust ETF's net assets surged to $223.4M at December 31, 2025 from $10.5M at December 31, 2024, fueled by massive capital inflows with shares outstanding rising from 250,800 to 6,300,100. However, NAV per share fell 15% to $35.45 from $41.67, driven by a net operational loss of $37.9M in 2025 versus a $7.2M gain in the prior partial-year period, primarily from $37.8M unrealized depreciation on XRP investments. XRP holdings expanded to 122.2 million units at fair value of $223.4M (cost basis $253.9M).

• ·Trust commenced operations on September 5, 2024
• ·No shares redeemed in either period
• ·No investment income reported in either period
• ·Sponsor’s Fee Waiver of $67K in 2025
• ·Net cash used in operating activities: $248.1M; provided by financing: $248.1M (2025)
• ·Q4 2025 showed sharp unrealized depreciation of $41.5M, contributing to overall ops loss

12-03-2026

Net assets increased 56% YoY to $160.4M at December 31, 2025 from $102.6M, driven by $107.1M in capital share issuances and shares outstanding more than doubling to 17.6M; however, operations showed a $49.3M net decrease due to $49.5M unrealized depreciation on SOL investments, contrasting with a $32.3M gain in 2024. NAV per share declined 37% to $9.09 from $14.33 amid SOL price weakness, while new staking rewards provided $1.6M income but expenses rose to $2.0M. Compared to 2023's $25.2M net assets, growth remains strong over two years but operational performance deteriorated sharply.

• ·No share redemptions occurred in 2023-2025.
• ·Cash balance remained at $0 throughout, with financing fully offsetting operating cash use via share issuances.
• ·SOL cost basis Dec 31, 2025: $175.0M vs fair value $160.4M (unrealized loss); Dec 31, 2024: $67.8M cost vs $102.6M fair value (gain).

12-03-2026

TEAM Inc's FY2025 total revenues grew 5.2% YoY to $896.5M, with IHT segment up 7.5% to $458.9M while MS increased modestly 2.8% to $437.6M. Operating income rose 38.8% to $14.1M, and Adjusted EBITDA improved to $60.7M from $54.3M; however, net loss widened 28.6% to $49.2M due to a $13.1M debt extinguishment loss and higher other expenses, with MS operating income declining 3.2% and free cash flow turning negative at $(20.6M) versus $13.3M prior year.

• ·Cash and cash equivalents declined to $18.1M from $35.5M YoY.
• ·Total assets decreased to $485.5M from $528.4M.
• ·Long-term debt reduced to $293.3M from $318.6M.
• ·Shareholders’ equity turned to deficit of $(24.5M) from $1.7M.
• ·Operating cash flow swung to $(11.3M) from $22.8M.

12-03-2026

Adicet Bio, Inc. reported a net loss of $116.8M for the year ended December 31, 2025, nearly flat at a 0% change from $117.1M in 2024, with total operating expenses declining 4% to $122.1M due to a 19% drop in G&A to $23.0M, while R&D expenses remained flat at 0% or $99.1M. However, interest income fell 46% to $5.8M, cash used in operating activities increased to $95.2M from $92.4M, cash and equivalents dropped to $38.9M from $56.5M, and total assets decreased to $192.4M from $220.2M.

• ·Common shares outstanding increased to 9.6M from 5.2M, driven by public offering of 4.4M shares net $74.8M.
• ·Stock-based compensation expense declined to $14.3M from $22.2M.
• ·Net loss per share improved to ($16.95) from ($21.33) due to higher share count.
• ·Short-term investments stable at ~$119.7M vs $119.8M.

12-03-2026

Wearable Devices Ltd. reported revenues of $647K for the year ended December 31, 2025, up 24% YoY from $522K in 2024, driven by growth in North America (up 39% to $385K or 60% of total) and Asia (up 36% to $118K or 18%). However, the company swung to a gross loss of $148K from a $85K profit in 2024 due to higher cost of revenues ($594K, up 64%) and inventory impairment ($201K, up 168%), while operating loss widened 7% to $8.3M and net loss increased 3% to $8.1M amid elevated R&D expenses.

• ·Entered non-exclusive reseller arrangement with Media Exceed Co., Ltd. in Japan in August 2025.
• ·Entered exclusive distribution agreement with Sky Commerce Co., Ltd. in South Korea in October 2025.

12-03-2026

Elicio Therapeutics reported a reduced net loss of $39.6M for the year ended December 31, 2025, improving 23.8% YoY from $51.9M, primarily due to operating expenses declining 16.2% to $37.7M, with R&D expenses dropping sharply 26.0% to $24.9M. However, G&A expenses increased 13.1% to $12.8M, cash used in operating activities remained nearly flat at $37.0M, total assets decreased to $25.9M from $28.2M, and net cash position slightly declined by $225K. Stockholders' equity improved to a positive $1.6M from a $11.3M deficit, supported by financing activities including stock issuances.

• ·Net cash provided by financing activities: $36.7M in 2025 vs $42.3M in 2024.
• ·Long-term debt, net: $9.4M at Dec 31 2025 vs $20.0M at Dec 31 2024.
• ·Warrant liabilities: $2.6M at Dec 31 2025 vs $2.8M at Dec 31 2024.
• ·Cash, cash equivalents and restricted cash: $19.3M at Dec 31 2025 vs $19.5M at Dec 31 2024.
• ·Weighted average common shares outstanding: 15,312,751 in 2025 vs 12,202,996 in 2024.
• ·Net loss per common share: $(2.58) in 2025 vs $(4.25) in 2024.

12-03-2026

Grayscale Ethereum Classic Trust (ETCG) filed its 10-K for the fiscal year ended December 31, 2025, disclosing it holds approximately 7% of ETC in circulation, with each Share representing 0.7850 ETC and 13,993,800 Shares outstanding as of March 6, 2026. Shares have historically traded at substantial premiums (max 458%, avg 98%) and discounts (max 77%, avg 45%) to NAV per Share since May 10, 2018, with a 28% discount as of December 31, 2025, due to lack of redemption program and volatility. The filing emphasizes risks including ETC price volatility, regulatory uncertainties, and potential Trust dissolution.

• ·Trust formed April 18, 2017; name changed January 11, 2019.
• ·Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole Sponsor effective May 3, 2025.
• ·No ongoing redemption program; creations in Baskets of 100 Shares.
• ·Shares trade on OTCQX; private placement Shares subject to Rule 144 six-month holding period.

12-03-2026

Andrew Yun resigned as Director and Chief Compliance Officer on February 27, 2026, citing concerns about the Company’s direction and unheeded advice on Board approvals and counsel. Abe Lim resigned as Director on March 3, 2026, without any stated disagreements. On March 2, 2026, the Board approved a temporary suspension of restaurant operations to address ongoing losses, closing 12 locations with potential for more closures and several in lease defaults.

• ·Company’s California restaurants at Buena Park, Eastvale, La Mirada, Irvine, and Ontario are in lease-related defaults.
• ·Resignation letter of Andrew Yun filed as Exhibit 17.1.

12-03-2026

Grayscale Dogecoin Trust ETF (GDOG), sponsored by Grayscale Investments Sponsors, LLC, filed its 10-K for FY ended December 31, 2025, detailing its operations as a passive vehicle holding Dogecoin (DOGE) with 624,700 shares outstanding as of March 6, 2026, and each share representing approximately 117.5835 DOGE. The Trust uplisted on NYSE Arca on November 24, 2025, after which shares traded with an average premium of 0.08% but also an average discount of 0.24% to NAV per share through year-end. Extensive risk factors highlight DOGE price volatility, regulatory uncertainties, and potential for shares to trade at premiums or discounts to NAV.

• ·Trust formed January 27, 2021; operations commenced January 30, 2025.
• ·Name changed to ETF on November 20, 2025; uplisted on NYSE Arca November 24, 2025.
• ·Sponsor changes: Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole sponsor effective May 3, 2025.
• ·SEC approved NYSE Arca generic listing standards September 17, 2025.

12-03-2026

First Horizon Corporation filed Articles of Amendment to its Amended and Restated Charter, creating a new series of Non-Cumulative Perpetual Preferred Stock, Series H, initially consisting of 4,000 shares with a $100,000 per share liquidation preference, for a total of $400M. The Series H shares carry a non-cumulative 6.750% annual dividend rate, payable quarterly commencing July 10, 2026, subject to board declaration. The amendment was authorized by the Board of Directors on January 27, 2026, and executed on March 6, 2026, without shareholder approval.

• ·Dividend Payment Dates: January 10, April 10, July 10, October 10 (commencing July 10, 2026)
• ·Board authorization date: January 27, 2026
• ·Senior executive authorization date: March 5, 2026
• ·Executed and signed: March 6, 2026

12-03-2026

Bitwise Ethereum ETF (ETHW), a Delaware statutory trust formed on February 16, 2024, filed its 10-K annual report for the fiscal year ended December 31, 2025, disclosing 15,280,000 shares outstanding as of March 3, 2026, and an aggregate market value of non-affiliate common equity of $269.3M as of the end of its second fiscal quarter. The Trust, which commenced operations on July 22, 2024, and trading on NYSE Arca on July 23, 2024, holds primarily ether with NAV referenced to the CME CF Ether-Dollar Reference Rate (New York variant) at $2,964.79 on December 31, 2025; no period-over-period financial performance data or declines were detailed in the provided sections.

• ·Trust formed on February 16, 2024; Sponsor Agreement dated July 9, 2024; Trust Agreement dated May 28, 2024.
• ·Commission file number: 001-42159; I.R.S. Employer Identification No.: 99-6361348.
• ·Baskets created/redeemed in blocks of 10,000 Shares based on Basket Amount of ether.
• ·Ether Trading Counterparties as of December 31, 2025: B2C2 USA Inc., Coinbase, Inc., Cumberland DRW LLC, FalconX, Flow Traders B.V., JSCT, LLC, Nonco LLC, Virtu Financial Singapore Pte. Ltd., Wintermute Trading Ltd.
• ·Constituent Platforms for Pricing Index as of December 31, 2025: Bitstamp, Coinbase, Gemini, itBit, LMAX Digital, Kraken, Crypto.com, Bullish Exchange.

12-03-2026

AMES National Corp's 10-K for 2025 reports a $656M investment securities portfolio with a weighted average yield of 2.26%, while fair value of states and political subdivisions obligations declined 3.4% YoY to $237M. Average total deposits grew modestly 0.6% YoY to $1.83B, but noninterest-bearing deposits fell 4.8% to $325M amid rate compression across categories; borrowings decreased sharply 39.5% to $60M. Asset quality was stable with nonperforming assets flat at $15.7M (1%) YoY and net charge-offs minimal at $357k or 0.03% of average loans.

• ·General obligation bonds fair value $135M (2025) vs $139M (2024), down 2.8% YoY
• ·Revenue bonds fair value $102M (2025) vs $107M (2024), down 4.4% YoY
• ·Average time certificates $333M (2025, up 8.4% YoY) at 3.78% rate (down from 4.12%)
• ·Nonaccrual loans $15.1M (2025, up 2.4% YoY from $14.8M)

12-03-2026

CompoSecure, Inc. reported net sales of $59.8M for the year ended December 31, 2025, an 86% YoY decline from $420.6M in 2024, driven by sharp drops in both domestic sales (-84%) and international sales (-93%), resulting in a gross margin contraction to 48% from 52% and a net loss widening to $136.0M from $83.2M. However, Adjusted EBITDA improved 13% to $171.8M from $151.4M, and Adjusted net income rose to $120.8M from $98.2M, reflecting non-GAAP adjustments for mark-to-market gains and transaction costs. In the prior year, 2024 sales had grown 8% YoY from 2023, but operating margins fell to 26% from 30%.

• ·Adjusted net income per share - basic: $1.09 (2025) vs $1.17 (2024)
• ·Adjusted net income per share - diluted: $1.00 (2025) vs $0.95 (2024)
• ·Mark to market adjustments, net: $208.1M (2025) vs $171.8M (2024)

12-03-2026

INTEST CORP reported total revenue of $113.8M for the year ended December 31, 2025, down 12.9% YoY from $130.7M in 2024, primarily due to declines in Process Technologies (-25.3% to $28.3M) and Electronic Test (-12.0% to $56.2M), while Environmental Technologies showed flat growth of 1.4% to $29.3M. Sub-markets were mixed, with strong gains in Life Sciences (+67.5% to $9.0M) and Industrial (+30.0% to $17.4M), but sharp drops in Auto/EV (-30.9% to $22.7M) and Semi (-26.2% to $36.0M). Gross profit fell 11.7% to $48.9M, though gross margin improved to 43.0% from 42.4%.

• ·Selling expense declined 3.4% to $16.8M (14.7% of revenue), Engineering and product development expense rose 10.4% to $9.4M (8.3% of revenue), General and administrative expense fell 5.7% to $22.2M (19.5% of revenue), Amortization of acquired intangible assets increased 31.5% to $3.3M (2.9% of revenue), Restructuring costs of $0.9M (0.7% of revenue) in 2025.
• ·Defense/Aerospace revenue down 6.9% to $14.3M, Safety/Security down 1.8% to $2.9M (flat), Other down 4.4% to $11.5M.

12-03-2026

Sherry Barrat, a director at Arthur J. Gallagher & Co., informed the company on March 6, 2026, of her decision to retire from the Board effective May 12, 2026, upon the election of directors at the 2026 Annual Meeting of Stockholders, and she will not stand for reelection. Her retirement is not related to any disagreement with the company's operations, policies, or practices. As a result, the Board size will be reduced from ten to nine members.

• ·Filing dated March 12, 2026, reporting event of March 6, 2026.

12-03-2026

Eastman Kodak Co reported FY2025 revenues of $1,069M, up 2.5% YoY from $1,043M, with strong growth in Advanced Materials and Chemicals (+17% to $316M) and Brand (+15% to $23M), while Print revenues declined 3% to $715M. Gross profit rose 14% to $232M (22% margin) from $203M (19%), but the company posted a net loss of $128M versus a $102M profit in 2024, driven by $171M other charges and higher restructuring costs. Cash and equivalents increased to $442M from $301M, supported by robust operating cash flow of $480M versus -$7M.

• ·Print Operational EBITDA improved to $3M (0% of revenues) from -$8M (-1%)
• ·Advanced Materials and Chemicals Operational EBITDA margin expanded to 12% from 6%
• ·Brand Operational EBITDA margin stable at 87% vs 85%
• ·Cash increased $141M net, with investing cash outflow reduced to $29M from $39M

12-03-2026

Bath & Body Works reported FY2025 net sales of $7,291M, down 0.2% YoY to $7,307M, driven by a 0.9% increase in stores sales to $5,582M but a 5.4% decline in direct sales to $1,395M, while international sales grew 4.9% to $314M. Reported operating income fell 11% to $1,126M from $1,266M, and net income decreased to $649M from $798M with diluted EPS at $3.11 versus $3.61. However, net cash from operating activities surged 24% to $1,102M, boosting free cash flow 31% to $865M and ending cash balances to $953M.

• ·Adjusted Operating Income declined to $1,156M from $1,266M YoY.
• ·Debt Leverage Ratio increased to 2.7x from 2.5x.
• ·Total ordinary dividends remained flat at $0.80 per share, with total paid $167M vs $177M.
• ·Total Selling Square Feet increased 2% to 5,493 thousand.

12-03-2026

Net assets of Grayscale Chainlink Trust ETF grew 229% YoY to $73,816 at December 31, 2025 from $22,437, driven by $70,805 in capital share transactions that increased shares outstanding 449% to 6,792,010. However, principal market NAV per share declined 40% to $10.87 due to a $18,889 unrealized depreciation on LINK investments, resulting in a net operational loss of $19,426 versus a $4,222 gain in 2024. Expenses rose 67% YoY to $509 amid sponsor fees, with no investment income.

• ·No investment income reported in 2025, 2024, or 2023.
• ·LINK holdings quantity increased to 6,029,727 at Dec 31, 2025 from 1,124,122 at Dec 31, 2024.
• ·No shares redeemed in 2025, 2024, or 2023.
• ·Cash remains at $0 end of 2025; all activities in-kind.
• ·Sponsor’s Fee waiver of $20 in 2025.

12-03-2026

For the three months ended January 31, 2026, Mission Produce, Inc. reported net sales of $278.6M, down 17% YoY from $334.2M, while gross profit remained essentially flat at $31.6M versus $31.5M. Operating income declined 73% to $2.5M from $9.3M due to SG&A expenses rising 31% to $29.1M, leading to a net loss of $0.1M compared to net income of $6.2M in the prior year. Balance sheet total assets grew 1.5% QoQ to $997.7M with inventory up 23% to $99.3M, but cash and equivalents fell 31% to $44.8M from $64.8M.

• ·Net cash used in operating activities increased to $3.0M from $1.2M YoY.
• ·Net cash used in investing activities improved to $11.8M from $14.9M YoY.
• ·Shares outstanding increased to 70,839,275 as of Jan 31, 2026 from 70,569,517 as of Oct 31, 2025.
• ·Stock-based compensation expense was $1.4M in the current period.

12-03-2026

American Outdoor Brands, Inc. and its subsidiaries entered into Amendment No. 3 to the Loan and Security Agreement with TD Bank, N.A. as Agent and Lender, effective March 10, 2026, amending the original agreement dated August 24, 2020 (previously amended March 25, 2022 and November 25, 2025). The agreement governs revolving advances, letters of credit, and security interests for borrowers including AOB Products Company and Crimson Trace Corporation, with guarantors such as Battenfeld Acquisition Company Inc. and others. No specific financial terms, changes in commitments, or performance metrics are detailed in the provided filing excerpt.

• ·Filing date: March 12, 2026
• ·Original agreement date: August 24, 2020
• ·Prior amendments: March 25, 2022; November 25, 2025

12-03-2026

LINKBANCORP reported net income of $33.5M for 2025, up 28% YoY from $26.2M, driven by net interest income growth of 4% to $104.3M, higher noninterest income from $11.1M branch sale gain, and loan growth of 13% to $2.53B net. However, provision for credit losses surged to $8.2M from $0.3M, NIM declined to 3.81% from 3.88%, loan yields fell to 6.27% from 6.38%, and noninterest-bearing deposits dropped 8% to $604M.

• ·Securities AFS increased to $262.6M from $145.6M.
• ·Interest-bearing deposits grew to $1.95B from $1.70B.
• ·Shareholders' equity rose to $306.4M from $280.2M.
• ·EPS basic $0.90 vs $0.71.

12-03-2026

Grayscale Bittensor Trust (GTAO), a Delaware Statutory Trust formed on April 30, 2024, issued its 10-K for FY ended December 31, 2025, reporting it holds approximately 0.3% of TAO in circulation with each Share representing ~0.0192 TAO; 1,907,800 Shares were outstanding as of March 6, 2026. Shares traded on OTCQX at substantial premiums to NAV per Share, with a maximum of 124% and average 65% premium from December 12-31, 2025, and 124% as of December 31, 2025, due to lack of redemption program, Rule 144 holding periods, and other factors preventing arbitrage. The Trust filed an S-1 in December 2025 for potential NYSE Arca listing as an ETF with redemption program, though not yet effective.

• ·Trust formed April 30, 2024; Sponsor changed to GSIS effective May 3, 2025 post-Reorganization.
• ·Index changed from Coin Metrics Real-Time Rate to CoinDesk Bittensor Benchmark Rate effective March 6, 2026.
• ·Shares issued in Baskets of 100 to Authorized Participants; currently no redemption program.
• ·Private placements only; OTCQX quoted but not listed on national exchange.

12-03-2026

Crane NXT, Co. (NYSE: CXT) announced the appointment of Jeffrey Benck, President and CEO of Benchmark Electronics, to its Board of Directors, citing his over 35 years of experience in technology leadership across software, services, and hardware. Current Director James L.L. Tullis notified the Board on March 6, 2026, that he will not stand for reelection at the 2026 Annual Meeting of Stockholders on May 21, 2026. Chairman John S. Stroup praised Benck's addition while thanking Tullis for his contributions.

• ·Jeffrey Benck holds a Master of Science in management of technology from University of Miami and a Bachelor of Science in mechanical engineering from Rochester Institute of Technology.
• ·Filing date: March 12, 2026

12-03-2026

NCR Atleos Corporation entered into a Supplemental Indenture on March 11, 2026, amending the terms of its 9.500% Senior Secured Notes due 2029 after receiving requisite holder consents via a consent solicitation tied to its pending merger with The Brink’s Company. The amendments redefine 'Change of Control' to exclude the merger and become operative immediately prior to closing, provided the merger consummates and consent fees are paid. While advancing the merger process, the filing highlights risks including failure to close, integration challenges, and regulatory approvals.

• ·Consent Solicitation expired at 5:00 p.m., New York City time on March 11, 2026
• ·Merger Agreement dated February 26, 2026
• ·Original Indenture dated September 27, 2023
• ·Amendments effective immediately upon execution but operative prior to First Effective Time of merger

12-03-2026

GE Aerospace delivered strong 2025 financial results with total revenue up 18% YoY to $45.9B, adjusted revenue up 21% to $42.3B, operating profit up 25% to $9.1B, adjusted EPS up 38% to $6.37, and free cash flow up 24% to $7.7B, alongside total orders up 32% to $66.2B growing backlog to ~$190B. The segments showed robust growth with CES revenue at $33.3B (orders up 35% to $54.4B, backlog ~$170B) and DPT revenue at $10.6B (backlog ~$21B). This proxy statement for the 2026 Annual Meeting proposes director elections, advisory approval of executive compensation, LTIP amendment, ESPP approval, auditor ratification, and addresses two shareholder proposals.

• ·CES revenue 75% from services
• ·Deployed ~1,450 LEAP-1A durability kits since certification
• ·Board changes: Welcomed Wes Bush, Steve Angel stepped down, Ed Garden not standing for reelection
• ·CEO Larry Culp's contract through 2027
• ·TSR 86% vs. S&P 500 Industrials Index 19%

12-03-2026

Inflection Point Acquisition Corp. IV (BACQU) filed its 10-K annual report on March 12, 2026, disclosing risks from potential debt obligations, including substantial cash flow allocation to principal and interest payments that could limit funds for dividends on Class A Shares, expenses, capital expenditures, acquisitions, and strategy execution. The filing highlights limitations on additional borrowing compared to less-leveraged competitors and potential control changes from issuing substantial Class A Ordinary Shares. It notes potential repayments of up to $750,000 in working capital loans from Inflection Point Fund I LP and up to $2,500,000 in Sponsor-related loans convertible into private placement units at $10.00 per unit, with consolidated financial statements provided from pages F-2 to F-24.

• ·Consolidated financial statements include Balance Sheets (F-3), Statements of Operations (F-4), Changes in Shareholders’ Deficit (F-5), and Cash Flows (F-6), with Notes from F-7 to F-24.

12-03-2026

On March 6, 2026, the Board of Directors of Avanos Medical, Inc. increased the target value of the annual long-term incentive grant for Chief Executive Officer David C. Pacitti from $5M to $5.5M under the 2021 Long Term Incentive Plan, effective beginning in 2026. This represents a 10% increase in the CEO's target incentive compensation. No other changes or declines in executive compensation were reported.

• ·Form 8-K filed on March 12, 2026
• ·Securities traded as AVNS on New York Stock Exchange

12-03-2026

Weis Markets, Inc. (WMK) filed a DEF 14A proxy statement dated March 12, 2026, for its Annual Meeting on April 30, 2026, proposing the election of five directors (Jonathan H. Weis, Harold G. Graber, Dennis G. Hatchell, Edward J. Lauth III, and Gerrald B. Silverman), ratification of independent auditors for the fiscal year ending December 26, 2026, an advisory vote to approve executive compensation, and an advisory vote on the frequency of such votes (recommending every three years). The record date is March 10, 2026, with 24,744,597 shares of Common Stock outstanding, requiring 12,372,299 shares for quorum. No financial performance metrics or period-over-period changes are disclosed in the filing.

• ·Annual Meeting location: 1000 South Second Street, Sunbury, Pennsylvania 17801, at 10:00 a.m. Eastern Daylight Time
• ·Directors elected by plurality vote with cumulative voting allowed via proxy card only
• ·Proxy materials available at https://www.weismarkets.com/financial.html or https://www.weismarkets.com/investor-relations

12-03-2026

Laird Superfood, Inc. completed its acquisition of Navitas LLC for $38.5M, funded by a concurrent $50M private placement of Series A Convertible Preferred Stock to affiliates of Nexus Capital Management LP. The transaction, approved by stockholders at a special meeting on March 11, 2026, positions the combined entity as a scaled platform in functional nutrition with enhanced product breadth and growth potential. While executives highlighted synergies and innovation opportunities, forward-looking statements caution risks including integration challenges and inability to realize anticipated benefits.

• ·Special stockholder meeting held March 11, 2026, to approve Transactions
• ·Navitas founded in 2003 with 20+ year history in superfoods
• ·Nexus Capital Management founded in 2013
• ·Legal advisors: Haynes and Boone, LLP (Laird); Paul, Weiss, Rifkind, Wharton & Garrison LLP (Nexus); William Hood & Company, LLC (financial advisor to Navitas); Brownstein Hyatt Farber Schreck, LLP (Navitas)

12-03-2026

iRhythm Holdings, Inc. (NASDAQ: IRTC) appointed Jason Patten to its Board of Directors, effective March 12, 2026. Patten, currently Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group since January 2022, brings extensive healthcare leadership experience from prior roles at UnitedHealth Group, OptumHealth, MoneyGram International, and Carlson Marketing Group. Chairman Abhi Talwalkar emphasized Patten's expertise in enterprise strategy, innovation, and partnerships to support iRhythm's growth toward a billion-dollar platform focused on AI, predictive care, and market expansion.

• ·Patten previously served as Chief Operating Officer and Senior Vice President of OptumHealth at UnitedHealth Group
• ·Patten holds an MBA in Business Administration from University of St. Thomas and a BS in Marketing from Minnesota State University, Mankato
• ·Investor Contact: Stephanie Zhadkevich (investors@irhythmtech.com)
• ·Media Contact: Kassandra Perry (mediarelations@irhythmtech.com)

12-03-2026

CACI International Inc entered into a Second Supplemental Indenture on March 12, 2026, issuing $500 million in additional 6.375% Senior Notes due 2033, increasing the total outstanding principal to $1.5 billion. The company received net proceeds of approximately $518 million, intended for repaying revolving credit facility debt used in the ARKA Group L.P. acquisition. The notes are senior unsecured, guaranteed by subsidiaries, with no reported issues in the offering process.

• ·Interest payable semi-annually on June 15 and December 15; first payment for Additional Notes on June 15, 2026, including accrued interest from December 15, 2025.
• ·Notes mature on June 15, 2033.
• ·Issued in private placement to qualified institutional buyers under Rule 144A.
• ·Base Indenture dated June 2, 2025; First Supplemental Indenture dated November 25, 2025.

12-03-2026

Axcelis Technologies, Inc. (Nasdaq: ACLS) announced David Ryzhik, Senior Vice President of Investor Relations and Corporate Strategy, as Interim Chief Financial Officer effective March 12, 2026, following James Coogan's departure to pursue a CFO role elsewhere; Coogan will remain until April 24, 2026, for a smooth transition. The company plans to engage an executive search firm for a permanent CFO hire. CEO Russell Low praised Ryzhik's expertise and his role in the pending merger with Veeco, while thanking Coogan for building a strong finance organization.

• ·David Ryzhik joined Axcelis in July 2024 with over 20 years of finance and investor relations experience.
• ·Axcelis has provided semiconductor solutions for over 45 years, headquartered in Beverly, Mass.

12-03-2026

Treasure Global Inc.'s subsidiary TADAA Technologies Sdn Bhd entered into a Software Enhancement Agreement on March 11, 2026, with Apexcode Innovations Snd Bhd to provide technology services for enhancing the Tazte Apps platform. The total contract price is RM11.7M (approximately $2.5M USD), with the first milestone payment of RM3.9M (approximately $0.83M USD); deliverables including source code must be handed over within 2 months. No immediate financial impacts or performance metrics are disclosed.

• ·Agreement includes development, upgrade, testing, deployment, and maintenance services per Appendix A
• ·Deliverables must meet Acceptance Criteria in Appendix A and be fully compatible with existing system
• ·Handover of deliverables (source code, object code, etc.) within 2 months from March 11, 2026

12-03-2026

Applied Optoelectronics, Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Raymond James & Associates, Inc. and Needham & Company, LLC, increasing the aggregate offering price for common stock from $250M to $500M. As of March 12, 2026, the Company has sold 2,476,307 shares for approximately $249,999,983, leaving roughly $250,000,017 available for future at-the-market offerings. Sales agents are entitled to 2% of gross sales prices as compensation, with the agreement terminable by either party.

• ·Shares to be sold in 'at the market' offerings via Nasdaq Global Market or other markets.
• ·Original Agreement dated February 26, 2026; prospectus supplement filed March 12, 2026.
• ·Registered under Form S-3ASR (Registration No. 333-283905).

12-03-2026

Molecular Partners AG reported zero revenues in 2025, a 100% YoY decline from CHF 5M in 2024 and CHF 7M in 2023, resulting in a net loss of CHF 62M, 14% worse than CHF 54M in 2024. While operating expenses fell 12% YoY to CHF 58M driven by R&D costs down 17% to CHF 40M and SG&A down 13% to CHF 15M, shareholders' equity dropped 43% to CHF 80M and total liquidity declined 38% to CHF 93M. Cash and equivalents improved 29% to CHF 83M amid net cash inflow from investing activities of CHF 73M.

• ·Restructuring expenses of CHF 2.7M in 2025.
• ·Net cash used in operating activities improved to CHF 51M from CHF 59M YoY.
• ·Net cash from investing activities of CHF 73M in 2025, driven by short-term deposit maturities.
• ·Basic and diluted net loss per share CHF 1.65 in 2025, slightly worse than CHF 1.59 in 2024.
• ·ADS depositary fees up to $0.05 per ADS for various services.

12-03-2026

WM Technology, Inc. reported FY2025 revenues of $174.7M, down 5% YoY from $184.5M, with net income declining sharply to $3.3M from $12.2M and EBITDA falling to $15.0M from $25.1M. Adjusted EBITDA decreased slightly to $39.8M from $42.9M, pressured by a 9% rise in G&A expenses to $76.9M and new $7.8M asset impairment charges, though product development costs dropped 23% to $28.1M and average monthly paying clients grew modestly to 5,190 from 5,077. Cash and equivalents improved to $62.4M from $52.0M, but operating cash flow fell to $26.2M from $36.7M.

• ·Working capital increased to $48.7M as of Dec 31, 2025 from $39.1M.
• ·Accounts receivable, net rose to $14.6M from $10.1M.
• ·Total costs and expenses up 2% YoY to $173.9M, reaching 99.6% of revenue vs 92.0% prior year.
• ·Net income attributable to WM Technology, Inc. was $2.0M (1.1% of revenue) vs $7.6M (4.1%) in 2024.

12-03-2026

Salesforce, Inc. entered into a Master Confirmation dated March 11, 2026, for uncollared Accelerated Share Repurchase (ASR) Transactions with an unnamed Dealer, establishing the framework under ISDA 2002 Master Agreement and Equity Derivatives Definitions. Specific terms for individual Transactions, such as Prepayment Amount, Initial Shares, Trade Date, Calculation Period, and Floor Price, will be detailed in future Supplemental Confirmations. No specific transaction amounts, volumes, or performance metrics are disclosed in this filing.

• ·Governing law: New York law.
• ·Exchange: New York Stock Exchange (symbol CRM).
• ·Transactions structured as Share Forward Transactions per 2002 ISDA Equity Derivatives Definitions.

12-03-2026

National Beverage Corp reported net sales of $264.6M for the three fiscal months ended January 31, 2026, down 0.9% YoY from $267.1M, while nine-month sales declined 0.5% YoY to $883.4M from $887.7M. However, gross profit rose 0.7% to $99.6M (three months) and 1.1% to $334.3M (nine months), driving operating income up 1.1% to $51.1M and $180.0M respectively, and net income up 3.9% to $41.2M (three months) and 0.9% to $143.3M (nine months). Cash and equivalents surged 62% to $314M, boosting total assets 18% to $792M and shareholders' equity 33% to $591M, though operating cash flow dipped 7% YoY to $136M.

• ·Trade receivables decreased to $97M from $104M year-over-year balance sheet comparison.
• ·Inventories increased to $96M from $85M as of May 3, 2025.
• ·Total liabilities declined 12% to $201M from $229M.
• ·Capital expenditures were $15M for nine months, down from $21M prior year.
• ·No dividends paid on common stock in nine months ended Jan 31, 2026 (prior year: $304M).

12-03-2026

Colgate-Palmolive elected Christopher S. Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, to its Board effective March 15, 2026, adding expertise in pharmaceuticals and healthcare. However, director Steven A. Cahillane will not stand for reelection at the May 8, 2026 Annual Meeting due to his new role as CEO of The Kraft Heinz Company.

• ·Dr. Boerner previously served as EVP, Chief Operating Officer (2023) and EVP, Chief Commercialization Officer (2018-2023) at Bristol Myers Squibb.
• ·Dr. Boerner to receive compensation as non-employee director per proxy statement filed March 26, 2025.
• ·Filing signed by Jennifer M. Daniels on March 12, 2026.